Brokerages Set Teladoc Health, Inc. (NYSE:TDOC) Target Price at $17.97

Shares of Teladoc Health, Inc. (NYSE:TDOC) have been given an average recommendation of “Hold” by the eighteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Twelve analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $17.97.

Several brokerages recently weighed in on TDOC. Barclays cut their target price on Teladoc Health from $25.00 to $20.00 and set an “overweight” rating on the stock in a research report on Friday, April 26th. JPMorgan Chase & Co. reduced their price objective on Teladoc Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 21st. Stifel Nicolaus dropped their target price on shares of Teladoc Health from $21.00 to $16.00 and set a “hold” rating for the company in a research report on Friday, April 26th. Evercore ISI reduced their price target on shares of Teladoc Health from $14.00 to $10.00 and set an “in-line” rating on the stock in a research report on Tuesday, July 9th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Teladoc Health in a research report on Friday, April 26th.

Teladoc Health Stock Performance

NYSE:TDOC opened at $10.03 on Thursday. The firm has a 50 day simple moving average of $10.62 and a 200-day simple moving average of $14.67. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.82 and a quick ratio of 3.74. The firm has a market cap of $1.70 billion, a PE ratio of -7.11 and a beta of 0.94. Teladoc Health has a 1-year low of $8.73 and a 1-year high of $30.41.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.90% and a negative return on equity of 10.13%. The business had revenue of $646.13 million during the quarter, compared to analysts’ expectations of $637.31 million. During the same period in the prior year, the firm earned ($0.37) EPS. Teladoc Health’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, equities analysts expect that Teladoc Health will post -1.05 EPS for the current year.

Insider Activity

In related news, COO Michael Willem Waters sold 5,793 shares of Teladoc Health stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.69, for a total value of $73,513.17. Following the completion of the sale, the chief operating officer now owns 64,881 shares in the company, valued at $823,339.89. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, COO Michael Willem Waters sold 5,793 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.69, for a total transaction of $73,513.17. Following the transaction, the chief operating officer now owns 64,881 shares of the company’s stock, valued at $823,339.89. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Laizer Kornwasser sold 10,411 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $12.69, for a total value of $132,115.59. Following the completion of the sale, the insider now directly owns 86,070 shares of the company’s stock, valued at $1,092,228.30. The disclosure for this sale can be found here. In the last three months, insiders sold 31,592 shares of company stock worth $383,854. 0.95% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Teladoc Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC increased its stake in Teladoc Health by 14.6% during the fourth quarter. Parallel Advisors LLC now owns 4,038 shares of the health services provider’s stock valued at $87,000 after purchasing an additional 515 shares during the last quarter. M&T Bank Corp grew its position in shares of Teladoc Health by 5.5% during the 4th quarter. M&T Bank Corp now owns 11,152 shares of the health services provider’s stock valued at $241,000 after buying an additional 584 shares during the last quarter. Van ECK Associates Corp raised its stake in Teladoc Health by 20.3% during the fourth quarter. Van ECK Associates Corp now owns 3,589 shares of the health services provider’s stock worth $77,000 after acquiring an additional 606 shares during the period. Ignite Planners LLC lifted its holdings in Teladoc Health by 6.9% in the first quarter. Ignite Planners LLC now owns 13,307 shares of the health services provider’s stock worth $198,000 after acquiring an additional 857 shares during the last quarter. Finally, Sunbelt Securities Inc. boosted its stake in Teladoc Health by 3.7% in the third quarter. Sunbelt Securities Inc. now owns 24,877 shares of the health services provider’s stock valued at $462,000 after acquiring an additional 899 shares during the period. 76.82% of the stock is owned by institutional investors and hedge funds.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.